Conroy Kevin T 4

What Happened
Kevin T. Conroy, a director of Abbott Laboratories (ABT), was credited with an award of 231 stock-equivalent units on June 30, 2026. The units are valued at $90.74 each, for a total notional value of $20,961. This transaction is recorded as an award/grant (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-30; filing date: 2026-07-01 (timely filed).
• Instrument: 231 stock-equivalent units (derivative award) at $90.74 per unit; total value $20,961.
• Transaction code: A (award/grant/acquisition).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote: Director fees were credited to a stock-equivalent unit account under a grantor trust; amounts are generally paid in cash at age 65 or upon retirement and earn the same return as if invested in Abbott stock.

Context
This was a routine director compensation credit (stock-equivalent award) rather than a purchase or sale of actual shares. Stock-equivalent units represent a notional interest tied to Abbott’s stock performance and typically convert to cash under the trust’s terms, so they don’t necessarily signal the insider buying or selling common stock.